Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes : A Phase 2b Randomized Clinical Trial
Authors' conclusion
Meaningful reductions in HbA1c levels were seen with bofanglutide in patients with T2DM; GIAEs were the most common and generally manageable.
Study context
- Population
- Adults with T2DM, drug-naive or on stable oral antidiabetic drugs (HbA1c 7.0% to 11.0%), 37 sites in China; mean age 50.8 years, HbA1c 8.35%, BMI 27.9 kg/m²randomized 1:1:1:1:1
- Participants
- 272 adults
- Comparison
- Bofanglutide vs semaglutide 1 mg QW
- Primary endpoint
- Change in HbA1c from baseline
- Follow-up
- Week 24
Methodological detailsphase 2b, open-label, active-controlled, multicentre
- Phase 2b
- Open-label
- Active-controlled
- Multicentre
Primary result
As reported in the abstract
Bofanglutide 12 mg Q2W
−1.87
95% CI −2.11%–-1.63% · %
Bofanglutide 18 mg Q2W
−2.28
CI −2.54%–-2.03% · %
Bofanglutide 24 mg Q2W
−1.94
CI −2.19%–-1.69% · %
Bofanglutide 24 mg QW
−2.32
CI −2.57%–-2.06% · %
Semaglutide 1 mg QW
−1.60
CI −1.85%–-1.35% · %
Each group vs semaglutide 1 mg QWTreatment difference, % (CI)
Bofanglutide 12 mg Q2W
−0.27(−0.61% to −0.08%)
Bofanglutide 18 mg Q2W
−0.68(−1.04% to −0.33%)
Bofanglutide 24 mg Q2W
−0.34(−0.70% to 0.02%)
Bofanglutide 24 mg QW
−0.72(−1.08% to −0.36%)
Safety
| Outcome | Bofanglutide | Semaglutide |
|---|---|---|
| Gastrointestinal adverse events (mostly grade 1 or 2)Range across bofanglutide groups | 81.8% to 87.3% | 51.9% |
Hypoglycemia
- No severe hypoglycemia
- Range across bofanglutide groups
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes : A Phase 2b Randomized Clinical Trial. Ann Intern Med. Published 30 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →